切换导航
  • 比较产品

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

main product photo

CellPore™递送管

用于CellPore™细胞转染系统的一次性机械穿孔递送管，可实现将目的物质高效递送至免疫细胞、HSPCs和hPSCs中。

只有 %1 左
率先评论此产品
¥4,486.00
添加并比较

产品号 #（选择产品）

产品号 #（选择产品）

用于CellPore™细胞转染系统的一次性机械穿孔递送管，可实现将目的物质高效递送至免疫细胞、HSPCs和hPSCs中。

产品优势

  • 使用CellPore™细胞转染系统的可控瞬时机械穿孔技术实现直接的胞质递送
  • 使用一次性递送管，可维持多种免疫细胞、干细胞和工程细胞类型的递送效率和细胞活率
  • 预组装的递送管包含用于处理细胞和目的物质混合物的递送插件及其收集管，从而简化您的设置和机械穿孔后的处理流程
  • 与CellPore™递送液配合使用，可确保从优化到常规运行均可获得可重复的结果
立即询价
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. CellPore™细胞转染系统
    CellPore™细胞转染系统
  2. CellPore™递送液
    CellPore™递送液
  3. CellPore™ FITC-Dextran
    CellPore™ FITC-Dextran
总览
实验数据
产品说明书及文档
相关材料与文献

总览

使用CellPore™递送管搭配CellPore™转染系统，可将多种物质，包括核酸（例如siRNA、mRNA、自扩增RNA）、核糖核蛋白（例如Cas9 RNP）、蛋白质和其他生物分子）递送至多种细胞类型中。这些递送管集成了特定尺寸的微流通道（压缩通道），利用机械形变实现细胞膜的瞬时无毒破坏（机械穿孔）。这种物理递送方法更为温和，是处理敏感和难转染细胞的理想解决方案，同时还能保持细胞的活率和功能。每个递送管均已预组装，包含用于处理细胞和目的物质混合物的递送插件以及用于简化机械穿孔后处理的收集管。每个CellPore™递送管可处理20至200 μL的样本体积。

CellPore™递送管目前提供两种压缩尺寸，每种尺寸均经过专门设计，可兼容多种细胞类型。

 

CellPore™递送管300兼容以下细胞：

  • 未激活的人pan-T细胞
  • 未激活的人CD4+ T细胞
  • 未激活的人CD8+ T细胞
  • 未激活的人调节性T细胞
  • 未激活的人自然杀伤 (NK) 细胞
  • 未激活的人B细胞
  • 人单核细胞
  • 人外周血单个核细胞（PBMCs）
  • 人CD34+造血干祖细胞（HSPCs）
  • 小鼠T细胞

 

CellPore™递送管500兼容以下细胞：

  • 人诱导多能干细胞（iPSCs）
  • 人胚胎干细胞（ESCs）

 

建议将CellPore™递送管与CellPore™递送液和CellPore™细胞转染系统配合使用，以确保在机械穿孔过程中获得最佳递送效率和细胞活率。

有关CellPore™的更多信息，包括CellPore™细胞转染系统中使用的胞内递送技术，请访问CellPore™总览页面。

 

应用
基因组编辑
 
品牌
CellPore™
 
研究方向
疾病建模，免疫学

查看更多 显示更少

实验数据

Optimizing CellPore™ Delivery Pressure for Efficient Transfection of hPSCs Using FITC-Dextran

Figure 1. Optimizing CellPore™ Delivery Pressure for Efficient Transfection of hPSCs Using FITC-Dextran

Newly passaged hPSC lines were cultured in complete mTeSRTM Medium for 7 days or until reaching 70% confluency. FITC-dextran was delivered to 3.5 x 105 cells per reaction in increasing pressure (5 - 25 psi). Immediately after delivery, cells were analyzed by flow cytometry to determine cargo delivery efficiency and cell viability. Conditions that maximized delivery efficiency with limited impacts to hPSC viability were determined to be 15 psi across 3 lines tested: (A) SCTi003-A hiPSC, (B) WLS-1C hiPSC, and (C) H9 hESC lines. The ”Endocytosis” condition indicates a control where cells are incubated in the presence of FITC-dextran without mechanoporation. “Untreated” indicates an unmanipulated sample without FITC-dextran. Data are presented as mean ± SD (n = 3).

The CellPore™ Transfection System Enables Reliable Cas9-RNP Editing Across a Wide Range of Cell Numbers

Figure 2. The CellPore™ Transfection System Enables Reliable Cas9-RNP Editing Across a Wide Range of Cell Numbers

RNP complexes targeting the B2M gene (1:2.5 Cas9:sgRNA mol ratio) were delivered to a range of hPSC numbers per reaction (from 3.5 × 105 up to 2 × 106) in 50 µL reactions at 15 psi. Cells were cultured for 2 days post-transfection to allow sufficient time for MHC-I surface marker knockout. Comparable viability, editing efficiency, and expansion were obtained across the cell number range tested for (A) SCTi003-A hiPSCs, (B) WLS-1C hiPSCs, and (C) H9 hESCs. No cargo indicates mechanoporation of hPSCs without RNP complexes at 3.5 × 105 cells per reaction. Data are presented as mean ± SD (n = 3).

Gene-Edited hPSCs Manipulated by CellPore™ and Maintained in mTeSR™ Plus Are of High Cell Quality

Figure 3. Gene-Edited hPSCs Manipulated by CellPore™ and Maintained in mTeSR™ Plus Are of High Cell Quality

(A) Gene-edited hESC (H9) and hiPSC (WLS-1C, SCTi003-A) maintained in mTeSR™ Plus on Corning® Matrigel® Matrix continue to exhibit classic hPSC morphology throughout the culture with densely packed, multilayered colonies. (B) hPSCs manipulated by CellPore™ (orange bars) harvested at Day 14 post-transfection were characterized for markers of the undifferentiated state, with > 90% of cells manipulated by CellPore™ (orange bars) staining positive for TRA-1-60 (left) and OCT4 (right), as determined by flow cytometry. Graphs show average expression (± standard deviation) results from analyses of 3 independent experiments. Genetic characterization using single nucleotide polymorphism array (SNPa) profiling confirmed no genetic perturbation across all 3 lines (data not shown).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
CellPore™ Delivery Cartridges 500
Catalog #
100-2175
Lot #
All
Language
English

法规声明：

The purchase of a CellPore™ Transfection System, CellPore™ Delivery Cartridges, and associated reagents (“CellPore™ Products”) conveys to the purchaser a limited, non-exclusive, non-transferable license to use CellPore™ Products, in accordance with STEMCELL's Terms and Conditions of Sale and all applicable laws and regulations, and solely for research-use-only applications (which applications exclude any commercial application or any therapeutic, prophylactic, diagnostic application, as well as any development and/or commercialization of products therewith or developed therefrom). CellPore™, SQZ™, Cell Squeeze™, and Empower Cells to Change Lives™ are trademarks of STEMCELL Technologies Canada Inc., following its acquisition of SQZ Biotech. Nothing in this agreement grants the purchaser any rights to use these trademarks without prior written permission from STEMCELL. STEMCELL or its licensor(s) grant no additional license rights other than those explicitly granted herein, and except for such limited license rights, all other intellectual property and proprietary rights in and to CellPore™ Products are and shall remain the exclusive property of STEMCELL and its licensors. The purchaser of CellPore™ Products agrees to prevent unauthorized use, access, copying, or disclosure of any intellectual property comprised in CellPore™ Products. The purchaser shall not, and shall not permit anyone to, copy, create any derivative work, reverse engineer, disassemble, decompile, or make improvements to CellPore™ products. Users and purchasers of CellPore™ products hereby grant to STEMCELL exclusive ownership and all rights, title, and interest in and to any improvements made, by purchasers or users, to the CellPore™ products (including any improvements by purchasers or users to the intellectual property directly related to CellPore™ products), provided however that the user or purchaser who makes the improvement retains a limited, non-transferable license to use such improvement for its internal, non-commercial research use, in accordance with this agreement, only so long as such user or purchaser is in compliance with this agreement. All data, information, and results (to the extent they do not constitute improvements of CellPore™ products) entered, stored, compiled, generated, and/or analyzed by purchasers of CellPore™ products using the CellPore™ products in accordance with all of the foregoing shall be the property of such purchaser. CellPore™ Transfection System and CellPore™ Delivery Cartridges (“CellPore™ Products”) are protected by patents in the U.S. and elsewhere. More information can be found at www.cellpore.com. The list of products and patents contained therein are subject to change as a result of routine prosecution and dependent on the patent life cycle as determined by the laws of each jurisdiction in which a relevant patent is in effect.

 

质量声明：

产品仅供科研使用，除非另有说明，不适用于人体或动物的诊断或治疗用途。欲获悉更多关于STEMCELL的质控信息，请访问STEMCELL.CN/COMPLIANCE。

Copyright © 2026 by STEMCELL Technologies. All rights reserved.

在线联系